Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Corporate governance
  • Shareholder information
  • Investor tools
  • Directors' shareholdings
  • SEC filings
  • Financial calendar
  • Financial results
  • Annual reports
  • Presentations & webcasts
  • Financial highlights
  • Strategy
  • FAQs
  • Investor contacts

You are here

• Home

• Investor relations

• Latest news collapse

  • 01 July 2009 IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe

    AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  June 2009

  • General presentation (1.85 Mb)

  • Other presentations

  Financial results collapse

  First quarter results 2009 were announced Thursday, 30 April 2009.

  • View first quarter results
  • View financial calendar

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

  Updated Currency Guidance 2009 collapse

  • View 2009 currency guidance

Not signed in

Page tools

• Print
• Bookmark this page

Share price